NCT06858878 (MARITIME-2) is a Phase 3 clinical trial of Maridebart cafraglutide in Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, sponsored by Amgen.

Who is sponsoring NCT06858878?

NCT06858878 is sponsored by Amgen.

What drugs are being tested in NCT06858878?

Interventions in NCT06858878: Maridebart cafraglutide, Placebo.

What condition does NCT06858878 study?

NCT06858878 studies Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight.

Is NCT06858878 still recruiting?

NCT06858878 is currently active, enrolled. Last updated 31 December 2025.

Last reviewed 2025-12-31 · How we verify

NCT06858878: MARITIME-2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

Active, enrolled Phase 3 Last updated 31 December 2025

What this trial tests

Phase 3 trial testing Maridebart cafraglutide in Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight in 1,105 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

17 March 2025

Primary endpoint
21 January 2027

16 April 2027

Quick facts

Lead sponsor	Amgen
Phase	Phase 3
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	1,105
Start date	17 March 2025
Primary completion	21 January 2027
Estimated completion	16 April 2027
Sites	187 locations across Italy, Japan, United Kingdom, Germany, Hungary, Poland, South Korea, Argentina

Drugs / interventions tested

Maridebart cafraglutide — full drug profile →
Placebo

Conditions studied

Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight — all drugs for Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight →

Sponsor

Amgen — full company profile →

Who can join

Adults 18 to 99, any sex, with Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Maridebart cafraglutide

Trials testing the same drug.

NCT07441252 — A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity · Phase 2 · recruiting
NCT07225686 — Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Th · Phase 3 · recruiting
NCT07226765 — Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressur · Phase 3 · recruiting
NCT07160257 — A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants Wit · Phase 1 · recruiting
NCT07037459 — Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity · Phase 3 · recruiting

Other Amgen trials

Trials by the same sponsor.

NCT07223190 — A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Ly · Phase 3 · not yet recruiting
NCT07493512 — Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer · Phase 1 · not yet recruiting
NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
NCT06987539 — A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Gen · Phase 2 · recruiting
NCT05909761 — Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregn · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06858878 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Amgen
Last refreshed: 31 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06858878.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing